Vortrag
Empagliflozin treatment substantially reduces total burden of heart failure and all-cause hospitalisations in patients with and without heart failure at baseline
Autor:in
Vortrag
Characterisation of the initial estimated glomerular filtration rate response to sodium-glucose co-transporter-2 inhibition with empagliflozin
Autor:in
Vortrag
Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories – Insights from the EMPA-REG OUTCOME trial
Speaker